Aurinia Pharmaceuticals (AUPH) Expected to Release Earnings on Tuesday

Key Points

• Aurinia Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast earnings of $0.22 per share and revenue of $83.61 million.
• In its latest quarter, Aurinia reported EPS of $0.28, beating the $0.24 consensus estimate, while revenue of $58.57 million fell short of the $80.45 million forecast.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $17.75 versus the stock’s recent price of $17.04.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP is expected to release its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.22 per share and revenue of $83.61 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to analysts' expectations of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. On average, analysts expect Aurinia Pharmaceuticals to post $0.91 EPS for the current fiscal year and $1.05 EPS for the next fiscal year.

Aurinia Pharmaceuticals Trading Up 1.1%

Shares of AUPH stock opened at $17.04 on Tuesday. Aurinia Pharmaceuticals has a fifty-two week low of $11.89 and a fifty-two week high of $19.25. The company has a 50 day moving average price of $16.37 and a 200 day moving average price of $15.60. The stock has a market capitalization of $2.27 billion, a P/E ratio of 7.44 and a beta of 1.60. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Weiss Ratings raised Aurinia Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday. TD Cowen raised their price objective on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, October 21st. Zacks Research cut shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 21st. Royal Bank Of Canada upped their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a "sector perform" rating in a report on Friday, August 7th. Finally, Wall Street Zen downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $17.75.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.